• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

An elite team of young, transpa­cif­ic sci­en­tists out of Har­vard and MIT starts plow­ing next-gen cell ther­a­py tech ...

7 years ago
Startups

Close­ly al­lied with (both) Mer­cks and Cel­gene, Sutro CEO Bill Newell is lay­ing out all his cards in a new IPO

7 years ago
Financing

FDA launch­es pi­lot pro­gram in sup­port of com­plex tri­al de­signs for drugs and bi­o­log­ics

7 years ago
Pharma

Am­gen vet Lau­ra Hamill takes com­mer­cial reins at Gilead amid ex­ec­u­tive shake­up

7 years ago
People

A faster treat­ment for tu­ber­cu­lo­sis? TB Al­liance launch­es piv­otal tri­al for four-drug reg­i­men

7 years ago
R&D
Discovery

Emer­gent snags opi­oid drug in $735M buy­out deal; Ger­many frets about post-Brex­it dis­rup­tion in drug mar­ket

7 years ago
News Briefing

Pop­u­lar biotech boost­ers get­ting mul­ti­mil­lion-dol­lar pay­outs on Wall Street as top an­a­lysts are wooed with big of­fers ...

7 years ago
Pharma

A for­mer fail­ure in PhII, the go-go FDA says it’s ready to con­sid­er an ac­cel­er­at­ed short­cut for Ul­tragenyx's UX007

7 years ago
R&D

Pfiz­er bris­tles at 'mis­lead­ing' com­ments from Big Phar­ma ri­vals Am­gen, Genen­tech on biosim­i­lars

7 years ago
Pharma

Sophiris says it’s ready to get back on track with lead drug af­ter pa­tient death — but ques­tions linger

7 years ago
R&D

As the maid­en biotech IPO on the HKEX fiz­zles, some in­vest­ment ex­perts see an up­side in tem­per­ing the hype

7 years ago
Financing
China

The boom­ing Boston/Cam­bridge biotech hub claims an in­dus­try-lead­ing role — no­body beats it at rais­ing record ...

7 years ago
Pharma

GSK spin­out KaNDy rais­es $32M to fund a break­through shot at a wom­en's health drug

7 years ago
Financing
Startups

Are­na's di­et drug castoff deemed safe in study; UK price over­seers say break­through CAR-T Yescar­ta is too ex­pen­sive

7 years ago
News Briefing

Tetraphase plots Q4 launch for first an­tibi­ot­ic af­ter long-await­ed OK for er­ava­cy­cline

7 years ago
Pharma

Bris­tol-My­ers pro­motes a com­mer­cial play­er to top sales job — re­plac­ing new Am­gen ex­ec Mur­do Gor­don

7 years ago
People

Alzheon IPO take two: Will in­vestors back a down­sized of­fer­ing from an Alzheimer’s biotech?

7 years ago
Financing

Vivek Ra­maswamy bags $100M in risk cap­i­tal to back his lat­est PhI­II gam­ble at Der­ma­vant — while Urovant dives in­to ...

7 years ago
People
Financing

Io­n­is, Akcea just got hand­ed a one-way tick­et to the end of the reg­u­la­to­ry line as the FDA re­jects volane­sors­en

7 years ago
Pharma

The new Cin­derel­la sto­ry: Can­cer pow­er­house Genen­tech lines up an NK al­liance with Af­fimed loaded with bil­lions in ...

7 years ago
Pharma

No­var­tis qui­et­ly hands top­i­cal treat­ment for rare dis­ease to Life­Max — lat­est in a string of out-li­cens­ing deals

7 years ago
R&D
Pharma

Mag­no­lia bags a $20M CPRIT grant to back tri­al work on new drug; Evotec lines up a new part­ner on rare ge­net­ic ...

7 years ago
News Briefing

Har­bour Bio­Med fol­lows can­cer drug deals with a hefty $85M Se­ries B backed by Sin­ga­pore's GIC

7 years ago
Financing
China

Drug prices in ads: Sen­ate pass­es amend­ment

7 years ago
Pharma
First page Previous page 1000100110021003100410051006 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.